Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.2%

Neg 0% Neu 88.2% Pos 0%

Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.